Ladies and gentlemen, welcome to the report on the Fourth Quarter 2023 Conference call. I'm Andrea, the Chorus Call operator. I would like to remind you that all participants will be in listen-only mode, and the conference is being recorded. The presentation will be followed by a Q&A session. [Operator Instructions] The conference must not be recorded for publication or broadcast. At this time, it's my pleasure to hand over to Dominik Heger, Head of Investor Relations. Please go ahead, sir.

Thank you, Andrea. Good afternoon or good morning, depending on where you are. I would also like to welcome you to our earnings call for the fourth quarter 2023 for the first time at 2 p.m. As always, I need to start out the call by mentioning our caution language that is in our safe harbor statement, as well as in our presentation and in all the materials that we have distributed earlier today. For further details concerning risks and uncertainties, please refer to these documents and to our SEC filings. With the Q4 results, we traditionally share an update on our strategic plan. Therefore, we have more to cover than in the other quarters. Given that we only have the 60 minutes, we need to limit the number of questions again to two in order to give everyone the chance to ask questions. It would be great if we could make this work again. With us today is Helen Giza, our CEO and Chair of Management Board, and Martin Fischer, our CFO. Helen will start with an update on our execution against our strategic plan. Martin will provide a review of the fourth quarter, and Helen will finish the prepared remarks with our outlook. Then, we are happy to take your questions. With that, Helen, the floor is yours.

Thank you, Dominik, and welcome everyone. Thank you for joining our presentation today and for your continued interest in Fresenius Medical Care. I'll begin my prepared remarks on Slide 4. A year ago, we laid out our strategic plan to turnaround and transform Fresenius Medical Care. This plan included ambitious structural, operational and cultural changes. Thanks to the hard work and dedication of our teams around the world, we have successfully executed on our commitment of fundamental transformation, making progress against all facets of our plan. We have done what we said we would do. A lot of the change we have undertaken would not have been possible without the implementation of our new operating model at the start of 2023. With our two distinct global segments, Care Delivery and Care Enablement, we are now operating with an end-to-end level of transparency and accountability that has not been in place previously. The new operating model enabled us to introduce new financial reporting with enhanced transparency. And throughout 2023, our commitment to our operational turnaround initiatives helped drive organic growth in both segments and improving operational performance. Our FME25 transformation program delivered savings ahead of schedule while ensuring our company becomes stronger and more resilient in the future. We have also undertaken a cultural transformation with greater emphasis on accountability. To this extent, we made two important leadership changes on our management board with Martin Fischer joining as CFO in October and Craig Cordola, our new Head of Care Delivery, joining in January of this year. I'm very excited about the new perspectives that they bring to our company and the impact that they are already having. In the fourth quarter, we finalized our change in legal form and are now operating in a simplified governance structure with strengthened rights of…

Thank you, Helen. And welcome to everyone on the call. I will recap our fourth quarter performance beginning on Slide 14. The fourth quarter developed in line with our expectations. We continued to deliver solid organic growth, revenue growth and contributions from both operating segments. USA market treatment growth was broadly stable and in line with our assumptions for the year when adjusted for the exit of less profitable acute contracts. These acute contracts exit demonstrate our continued focus on driving profitable growth. Earnings in the fourth quarter were supported by strong FME25 savings, as well as proceeds from the Tricare settlement in the US and improved pricing and Care Enablement. In Care Delivery US, our value-based care business continued to expand. While this development was revenue supportive, we experienced a negative earnings contribution in the fourth quarter driven by CKCC retrospective trend adjustments. As Helen described earlier, we continued to make important progress on our portfolio optimization plan, with the divestment of NCP and Argentina closing in the quarter. Turning to Slide 15. In the fourth quarter, we delivered revenue growth of 7% at constant currency. Organic growth of 3% was mainly driven by price in Care Delivery and both volume and price in Care Enablement. The Tricare settlement and the closed portfolio optimization activities are not included in organic growth. During the fourth quarter, operating income, on a guided basis, improved by 18%, and our group margin improved to 11%. Normalized for Tricare contribution, our margin in the fourth quarter would have been 7.8%. Earnings development was supported by accelerated FME25 savings of €114 million in the quarter, as well as net proceeds from the Tricare settlement of €181 million. From an operational perspective, the fourth quarter developed in line with our expectations, as we had previously flagged.…

Thank you Martin. On Slide 21, you can see our FME25-related savings and costs since the program's initiation. As I discussed earlier, our FME25 transformation has successfully delivered sustainable savings through 2023. We are fully on track to deliver our savings target of €650 million by 2025. Looking ahead to 2024 specifically, we anticipate €100 million to €150 million in incremental sustainable savings from FME25 by year-end. We expect also €100 million to €150 million of one-time costs for the execution during 2024. This leaves us with €150 million to €200 million in incremental sustainable savings until the end of 2025 with investments of €80 million to €100 million in the same year. Turning to Slide 22. We want to continue to be very transparent about the assumptions we are making in our annual outlook. In 2023, both our revenue and operating income were supported by the Tricare settlement and divestments that we have closed in the meantime. As these will not repeat in 2024, we are excluding them from our outlook base. We have been asked why the Tricare settlement is not being treated as a special item. I want to clarify that as the initial write-off and the constrained revenues and earnings were part of operational business and never classified as a special item in the past, this required us to leave it as an operational item. To define our outlook, we have made certain assumptions. We are assuming positive US same market treatment growth of 0.5% to 2% over the course of the year. This excludes annualization effects from exited acute contracts. Based on this and the CE volume growth, as well as positive support from pricing in both segments, we expect business growth contributions of €400 million to €500 million, the FME25 savings contributions I mentioned…

Thank you, Helen, thank you, Martin, for your presentation. Before I start the Q&A, I would like to remind everyone to please limit it to two questions. And with that, I hand over to Andrea to give you the instructions.

We will now begin the question-and-answer session. [Operator Instructions]

And the first question comes from Victoria from Berenberg.

Thanks for taking my question.

Hi, Victoria.

Hi. So, my first question is just on the -- if you could give us an indication of Q1, like-for-like growth, just so we can get a sense of how you are coming to the 0.5% to 2% guidance for the year? And then, the second question is just, you guys have closed 72 clinics in 2023. What is the outlook for clinic closures in 2024? And how is this helping your utilization rates?

Thank you.

Thanks, Victoria. I'll take both of those. Regarding the volume question and maybe the sizing of how we see the guidance, like the competition I think we're encouraged by the market volume trends. We did see a tick-up in mistreatments in Q4, kind of weather and kind of flu and COVID effects in Q4, which really unfortunately impacted our respective volume. While we've made tremendous strides in controlling our labor and improving our efficiencies in 2023, we still have some markets and some metro areas that are constrained and are impacting our growth. Growth truly is a top priority for our CD US team. And I think with a different approach by a new leader, we're really encouraged by some of the early actions that are being taken there. Obviously, some of that mistreatment flu in Q1. We didn't have a flu season last year. We have a mild one this year. So obviously, with Q1, we always expect that to be a bit lower. But that will ramp up over the year and are really optimistic by what we are seeing on the new patient start numbers. Oh, I'm sorry, second question. The 72 clinics for 2023, when we put this plan out there, we sized between 50 and 100, and perhaps, as you've come to expect from me, we've landed somewhere in the middle there. We don't have another ongoing major clinic closure plan, but obviously, as we are looking at our clinic portfolio and underperforming clinics, we will constantly keep a keen eye on those. But I think they will be in the small single digits, not a major program like we've seen in '23.

Great. Thank you.

Thank you. The next question comes from Richard Felton from Goldman Sachs.

Yeah, thank you. So, my first question is on the CE margin. So, it seems like transactional FX was a pretty big headwind to the business in FY '23 and is going to be a headwind again in 2024. So, my question is, do you still feel confident about achieving the 2025 margin bands for Care Enablement that you outlined at your CMD, or has transactional FX moved against you so much that that's going to be hard to achieve? And then, my second question, I know you don't guide specifically on revenue per treatment for US dialysis, but could you help us think about some of the key moving parts, whether it's payor mix, reimbursement, or commercial negotiations as we think about revenue per treatment into 2024? Thank you.

Thanks, Richard. Martin, do you want to take the transaction piece and our confirmation of our CE margin bands, and then I'll take the revenue per treatment one?

Yes, sure will. So, thanks, Richard. On the transactional FX, you saw that we included another €50 million in our '24 outlook. You also saw that this is coming down year-over-year, and yes, we are hedging against those topics. Certain topics we cannot hedge. Others, we do absolutely hedge, but there's uncertainties like in things like Russia. We are confident that we will come into our margin band in 2025 and we are offsetting those transactional headwinds with our performance improvement and the transformation program.

Thanks, Martin. And Richard, on RPT, I mean maybe just unpacking that a little bit, we obviously know we've seen from a PPS reimbursement rate at 2%, we are assuming moderate increases on the rest of the book of business. We are continuing to see an increasing Medicare Advantage book of business sitting at around 40% now, which is really encouraging. And our commercial mix has stayed quite sticky throughout. So, we're sitting at around 11% on our commercial mix there. So, I think the moving parts there, and we're seeing nice trends, quite consistent. I think you all know we're disappointed with the reimbursement rate on PPS. We continue to work that. And then, in terms of major, no major contracts up for renewal, a couple of smaller regional ones towards the end of 2024. But I think we have a nice line of sight into that RPT and it's developing quite nicely.

Great. Thank you very much.

Thank you. Next question comes from James from [indiscernible].

Hi. Thanks for taking my questions. Two, if I may, please. Firstly, perhaps it would be great if you could have just sort of comment on the margin improvement on an adjusted basis in 2023. And can you help me understand the impact from depreciation and amortization? Because it looks as a percentage of revenues, that was around a 50 basis points improvement as that was lower by around €100 million, which seems to be about half the adjusted margin gains. So, I was just kind of wondering if you expect further margin gains, some lower D&A in 2024 disposals and how that differs by segment. And then my second question is just on GLP-1. Just kind of curious what your thoughts are on what the industry impact could be from the FLOW study, which I think is due in the first half. Thank you.

Yeah. Why don't I take the second one on GLPs, and I'll give Martin perhaps some time to pull what he can here on the depreciation question if we have something of that level of detail. So look, on GLP-1, I think, as you heard in the closing comments there, we've got no new data. We continue to unpack all the different scenarios and analysis, and still keep coming back to this balanced overall or neutral and with this kind of decade to kind of see the full effect. And I think we are seeing it exactly the same as the industry is seeing it. We keep breaking it down into our three buckets of medical effectiveness, prescription rates, and patient adherence. And obviously, the bigger part of that is the medical effectiveness where we do think that these drugs will slow the progression to ESRD, but that will be countered by the cardiovascular protection where we should get more CKD patients coming in. Obviously, there's unknowns on prescription rates. While we think pricing and access will normalize over time, we still don't understand the side effect profile on this patient population. And we -- like with SGLT2s, they've been on the market a decade, we have a very slow, a small uptick -- kind of uptake, with it being around 8% there. For what we can see in our patient population, we have about 5% of our patients taking GLP-1s, but what we also see is a high drop-off rate of those patients taking GLP-1s as well. And then of course, for patient adherence, we know these patients are taking, with their comorbidities already taking a lot of other prescriptions. We're still not sure -- we don't think that they'll be at 100% adherence, which obviously for this, where they have to take it for the rest of their lives. We'll kind of have to see how that plays. All of that said, I mean our story is still the same. We still see it balanced overall. With regard to FLOW trial, obviously, there's no new data. We do expect it to be read out in half one. We expect that to be maybe more toward the back end of half one, but we're obviously waiting for that data like everybody else is, and in real time, we will unpack it and kind of compare it against the assumptions we've all made. But we continue to analyze it and push the boundaries on all those different assumptions.

Okay. So, on the margin improvement, the biggest contributors that we see is labor efficiencies, as we outlined and Helen mentioned before, that was predominantly driven by CD. In addition, we have also price, as you know, supporting our development in CD, and we have the supporting FME25 savings that are predominantly contributing to the margin expansion. When we look at CE, it is price and volume growth that is supporting the margin. And similarly, we have also therein supporting the savings, especially that we drive in our, let's say, G&A area that also contribute. The depreciation topic is mainly a CD topic. On the details of the depreciation and amortization topics, I would have to come back to you and [I'll answer that] (ph).

Thank you.

So, the next question comes from Hassan from Barclays. Hassan, please.

Hi, thank you for taking my questions. I have a couple, please. So firstly, could you quantify the headwind in Q4 from the CKCC model retrospective changes? And to what extent is this still an attractive business? Will you consider some entity exits over the next couple of months? And secondly, Helen, when you set out your CE targets at your Capital Markets Day in April last year, contract repricing was a key lever that you laid out. Where are you on this plan? And how much of a tailwind will this represent to margins in 2024? Thank you.

Thanks, Hassan. Why don't we take the CKCC piece into two parts? Let me have Martin speak to the headwind itself, and I'll pick up on the back end of that to speak about the attractiveness of the market and how we're looking at that. And I'll take the CE pricing question as well.

Super. So, on the CKCC topic for the quarter, we incurred about a €60 million loss of negative operating income in the quarter. And this is predominantly driven by changes in timing in actuarial assumptions that we took. And as with any of those topics and the maturity of the business, when you talk about insurance entities, those assumptions do change within quarters and we look normally at the business on an annual or on a contractual and lifetime cycle. So, those €60 million is something that also when you consider the full year turns our full year CKCC into a €10 million negative that you can like assume after quarter four.

Thanks. So, in terms of the attractiveness, obviously, this isn't our first rodeo on being surprised with retroactive adjustments on the government programs. We feel that we had better line of sight into these, and of course, we were positive through Q3, and then when the retroactive adjustments came in, they had a big swing. For us, this is an important market for VBC, and we get to get insight into both ESRD and CKD populations, but clearly, we have to get under these KCEs or kidney care entities' performance in more detail. There is a path coming up in the first part of this year where we can exit those underperforming KCEs, and we will obviously take a hard look at those. Overall, we do see the value-based care book of business and that strategic driver as important for us and particularly in MA, and we are making significant progress there which we like, and we have picked up some pretty significant new contracts. But obviously, at the end of the day, we want to make sure that we get the positive contribution that we expect. So, I think we'll continue to put more color on this, Hassan, as we go through the year, particularly as we evaluate the KCE entities. Obviously, on CE, we know that we were starting from a low -- sorry, switching to your second question, we know, on CE, we were starting from a low base, and I think we made some really nice progress in '23 on pricing and overall efficiencies. As we know, the inflationary impact and the transaction impact muted that. But we are sharpening our pencils and tightening what we're doing on pricing. And within '23, even though you only get to see the net effect, there was about €100 million of pricing favorability actually, which equated to around 3% on average. And that will continue into 2024, where we're projecting a low- to mid-single digit price increase for CE. Now, the challenge there is we can't just go out and take 5% on every contract immediately. We have to wait for some of these, whatever percentage it would be, we have to wait for these contracts to open up and obviously evaluating every contract on its own merits and understanding what kind of price we can take on it. So, this will roll up -- kind of ramp up over time as the contracts and tenders come up. But we are committed and confident with the plan for the CE margins. And of course, we are working even harder to create tailwinds to offset the headwinds, which I think we did a nice job of in 2023. But obviously, as we've outlined, we do expect a step up in margins for CE for 2024 and a committed to the margin band for 2025.

Perfect. Thank you.

Thank you, Hassan. The next question comes from Lisa from Bernstein.

Hi. Just a few questions. One, can you comment on where your private mix sits today and how that's changed recently? And also, if you could comment about MA uptake as a percent of your total Medicare patients? And then last question is, what would your US growth been in Care Delivery excluding the exit from the acute care contracts in the quarter? Thanks.

Thanks, Lisa. I'll take three questions. The commercial mix is sitting at around 11%. We've seen that to be quite sticky. Tiny little bits of improvement, but really sitting around there. MA, we don't do it as a percentage of total Medicare, we do it as a total book of business, and that's sitting around 40%. So again, we've seen some nice tick-ups there kind of along the way and improvement. I think US treatment growth adjusted would have been flat. We had around 50 basis points, 60 basis points of impact for the acute contact. So that would have taken us to flat on the organic treatment growth.

Okay. Thanks for that.

Thank you, Lisa. Next question comes from Veronika from Citi.

Hello. Hi, guys, good afternoon. I hope you can hear me okay. Two questions for me. First, please, on same market treatment growth? And obviously, thank you for all the color you've given us in terms of the performance excluding acute care contracts. If I look at Q3 and Q4, you are still undergrowing [EBITDA] (ph) by sort of 50 basis points to 70 basis points. Just curious, Helen, why you think that's the case? And is the ambition to narrow that gap, or are you happy with the type of growth that you're seeing at the moment on a kind of [margin-related] (ph) basis? And then, my second question, and I appreciate you might not enjoy answering this one, I'm going to ask it anyhow. Obviously, if I compare your Baxter -- if I compare your product business to the Baxter product business, Baxter have made a substantial amount of progress on margin improvement in the back half of 2023. You guys haven't done that. I know it's slightly unfair, but what do you think are the key differences? Is it really just the FX that's hindering you from showing as much progress in margin as they have, or is there something else we need to be aware of? Thank you, guys.

Thanks, Veronika. It's hard to hear you, but I think I got your questions kind of crackling on the line. Same market treatment growth compared to DaVita, obviously, we've seen those results. Clearly, we had an underperformance in the Q4 compared to that. And I think I'd break it down into two things. The market dynamic is strong. We are seeing strong new patient starts. I think we ended up being impacted in the quarter with the mistreatment, as I mentioned. And I think we got a bigger impact on that. Additionally, obviously, through 2023, we are still focused on a turnaround of our Care Delivery operations in the US. And while we have made significant progress, we do still have some constrained clinics and some labor challenges that we are working through. Craig and the team are 1,000% focused on this growth number. We're tearing apart our processes and approaching it in a different way. So, I'm confident that we will get under this and fix the remaining operational challenges that we have to there. But I think where I'm encouraged is the overall market is there. We are working through unconstraining clinics in real time. We've already seen progress in January and February in markets that had been constrained for quite some time, we are fixing and fixed. So that's why I feel very confident about our volume outlook and closing that gap. As you rightly say, we have some adjustments for the acute contracts. There will be a small annualization for that in 2024. We also, I think, like-for-like have closed. When you look at the cumulative effect of closing clinics, we're sitting in about the same spot. So, we're optimistic about what -- we know what the work is that needs to be done and we're optimistic about the results that we need to deliver here. Yeah, the Baxter question, in the same way we compare ourselves all the time, of course, to the two different peers that you've mentioned. When we reviewed ourselves there, I think we had a -- we felt that we had a stronger beat in share and positioning and margin. So, I don't know if we're comparing it like-for-like, as you mentioned there, Veronika, but we had good volume growth, and it could just be a transaction effect there. But our comparison was that we had a really strong quarter.

Understood. Thanks so much, guys.

Yeah.

Thank you, Veronika. Next question comes from Hugo from BNP.

Hi, guys. Thanks for taking my question. I have two. First on Care Delivery International. We've seen a price impact dropping from mid-teens to mid-single digit in Q4. Just wondering what the impact. What's the driver behind that? Is there any tender kicking in? Anything we should have in mind? And maybe quick follow up on that, if you can update us on the China VBPs? And second question is on the growing contribution of value-based care, can you give a bit more quantitative details on the positive operating income contribution that you expect for 2024? I mean, the direction of travel is not really easy to model here given the 20% increase in costs under management, 10% increase in patient, but over 40% revenue growth. So, if you can give us some details, yeah, that would be much appreciated. Thank you.

Hugo, could you please repeat your first question? We have some technical issues here.

We've got your China VBP question. We couldn't hear the first part of your question Hugo.

The first one was on the price impact for Care Delivery International, which is about 5.5% in Q3 -- in Q4, sorry, while you were running at low-double digit to mid-teens for the first nine months. So, just wondering what's driving that decline.

Okay. Let me see if we can snag that CDI price explanation while I'm filling in here. The China VBP, we did preempt that and we also have moved to local manufacturing in China. While we expect to be some impact from that, quite small. So, we're thinking that the China VBP impact is about €10 million to €15 million and included in our outlook here. On the CDI, the price, I think that has to be an Argentina hyperinflation effect, where we exited in Q4. So, I think that comes out of organics. So, I think that's the technical adjustment there. It's just really Argentina. On VBC, clearly, we've given you a few more metrics than we have, but we're not disclosing the operating income contribution specifically for VBC for '24, other than we expect it to be positive. It's not an operating segment, so we wouldn't get into that level of detail there of disclosure.

Okay. Thank you.

Thank you, Hugo. Next question is from Oliver from Oddo.

Yeah. Good afternoon. Thanks a lot for taking my question. The first one is also on VBC and the phasing of earnings. So historically, you commented on having an EBIT margin of around 1% for the medical cost under management. We now see or basically you plan to show a step up in the medical cost under management from the €6 billion to €8 billion in 2024. So, can you explain us about the phasing? How long does it take to realize some of the respective profits? Do you expect the bulk of the delta to come in -- up from '25, or do you see also pro rata increase in the profits in '24? The second question is on the high-volume hemodiafiltration. Do you -- very conceptually, do you expect to be rewarded for this innovation by a higher price, or do you really think that you use better technology to gain market share? That's from my side. Thank you.

Martin, do you want to take the VBC question?

Yes. Thank you, Oliver.

And I'll take the HDF question.

Yes. I mean, you're right, we are ramping up here our cost under management from €6 billion to €8 billion. And yes, it will take some time until we generate savings out of that additional cost under management. So, I would not figure in a big contribution into '24, and only a smaller one into '25. But I think we are rather positive and confident in our ability to manage that well.

Oliver, On the HDF, we're really excited about that. I mean, obviously, this is a gamechanger for the industry to improve mortality by 23 months -- 23%, which translates to about 18 months. That is massive. Obviously, we got really thrilled with the FDA approval, which came kind of a few weeks earlier than we anticipated. Obviously, right now, we are working through our go-to-market strategy, both from a product pricing, but also a health economics perspective on what this means for the kind of the, not just the product business, but for the service business as well. So, we are planning a full commercial launch in 2025. As you can imagine, there's a lot of interest in this technology. It is significant innovation and maybe some of the first innovation we've had here in quite some time. So, we are thrilled, excited, a gamechanger. Obviously, we will update. I'm not going to disclose my commercial strategy and pricing strategy here, but we will update as we get closer to launch here.

Okay, great. Thank you. A very, very quick follow-up on this. So, it does mean if you bring this technology into your value-based care agreements, that there is kind of resettlement of the terms, or does it bring more benefit to your side?

I think done right, this brings benefit to the entire industry, Oliver.

Hence, therefore, also to your side. Thank you very much, and get well soon.

Thank you. I'm sorry about the coughing today, everybody.

Thank you. We have one last question -- time for one last question. Marianne from Bank of America is the next one.

Thank you for squeezing me in. Just one question on your optimization plan of the portfolio. Maybe if you could remind us the type of assets you're looking to divest and how advanced you're in the program? So, if you feel there is much more to do here in 2024? Thank you.

Thanks, Marianne. Happy to take that question. Obviously, when I started to take a look at the portfolio a year or so ago, we put them into two buckets. It was those assets that were non-core to us and that we didn't feel we were the best owner of that asset, even though they're very nice assets and, obviously, have some profitability associated with them. Then, we had other assets, mainly in Care Delivery International, that were in markets where they were unprofitable or the underlying structural reimbursement or profitability had changed or of a scale where we didn't feel that we could invest to grow or turn them around. So, what you will have seen executed on in 2023 is a little bit of both. On the non-core, I mean, the bigger ones there are obviously NCP and Cura. But on the clinic exits and international, you will have heard the increasing long list of markets and countries that we are exiting. We are not done. There will be more to come. We can't put color on them until we have signed agreements and then of course they close afterwards. So, as we did in 2023, we will continue to provide color on those divestments when done. I think the overall sizing that we put out there, I mean I know subject to exchange rates if you think about Argentina and hyperinflation as an example, but as we think about the sizing that we put out there, that's still good and we will provide progress as we go through 2024. But clearly, for us, as we're exiting these at speed, the focus and the distraction effort is clear for us and I think gets us back focused on the core business and where we can grow and profitably grow there. So more to come, a lot still in the works and we'll provide updates in future quarters. So, thank you.

So, we did run out of time. I'm sorry for that. I apologize to those that are still in the queue. I'm sorry for that. Thank you for listening in, and for your great questions, which we appreciate a lot. And we'll see most of you hopefully soon, and very soon tomorrow, I hope ideally, and looking forward to that. Thank you. Take care.

Yeah, thanks, everybody.

Thank you.

Take care.

Take care.

Ladies and gentlemen, the conference is now concluded. Thank you for choosing Chorus Call, and thank you for participating in the conference. You may now disconnect your lines. Goodbye.